These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35354248)

  • 1. TAL1 cooperates with PI3K/AKT pathway activation in T-cell acute lymphoblastic leukemia.
    Thielemans N; Demeyer S; Mentens N; Gielen O; Provost S; Cools J
    Haematologica; 2022 Oct; 107(10):2304-2317. PubMed ID: 35354248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting dual oncogenic machineries driven by TAL1 and PI3K-AKT pathways in T-cell acute lymphoblastic leukemia.
    Lim FQ; Chan AS; Yokomori R; Huang XZ; Theardy MS; Yeoh AEJ; Tan SH; Sanda T
    Haematologica; 2023 Feb; 108(2):367-381. PubMed ID: 36073513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CASZ1 upregulates PI3K-AKT-mTOR signaling and promotes T-cell acute lymphoblastic leukemia.
    Cardoso BA; Duque M; Gírio A; Fragoso R; Oliveira ML; Allen JR; Martins LR; Correia NC; Silveira AB; Veloso A; Kimura S; Demoen L; Matthijssens F; Jeha S; Cheng C; Pui CH; Grosso AR; Neto JL; De Almeida SF; Van Vlieberghe P; Mullighan CG; Yunes JA; Langenau DM; Pflumio F; Barata JT
    Haematologica; 2024 Jun; 109(6):1713-1725. PubMed ID: 38058200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TAL1 mediates imatinib-induced CML cell apoptosis via the PTEN/PI3K/AKT pathway.
    Wu Y; Hu Y; Yu X; Zhang Y; Huang X; Chen S; Li Y; Zeng C
    Biochem Biophys Res Commun; 2019 Nov; 519(2):234-239. PubMed ID: 31493871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TAL1 activation in T-cell acute lymphoblastic leukemia: a novel oncogenic 3' neo-enhancer.
    Smith C; Goyal A; Weichenhan D; Allemand E; Mayakonda A; Toprak U; Riedel A; Balducci E; Manojkumar M; Pejkovska A; Mücke O; Sollier E; Bakr A; Breuer K; Lutsik P; Hermine O; Spicuglia S; Asnafi V; Plass C; Touzart A
    Haematologica; 2023 May; 108(5):1259-1271. PubMed ID: 36632736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TAL1 hijacks MYCN enhancer that induces MYCN expression and dependence on mevalonate pathway in T-cell acute lymphoblastic leukemia.
    Tan SH; Tan TK; Yokomori R; Liao M; Huang XZ; Yeoh AEJ; Sanda T
    Leukemia; 2023 Oct; 37(10):1969-1981. PubMed ID: 37591943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory mechanisms and context-dependent roles of TAL1 in T-cell acute lymphoblastic leukemia.
    Ong JZL; Tan TK; Wang L; Tan SH; Sanda T
    Haematologica; 2024 May; 109(5):1359-1372. PubMed ID: 37855064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiR-7 Functions as a Tumor Suppressor by Targeting the Oncogenes TAL1 in T-Cell Acute Lymphoblastic Leukemia.
    Sun H; Zhang Z; Luo W; Liu J; Lou Y; Xia S
    Technol Cancer Res Treat; 2020; 19():1533033820934130. PubMed ID: 32633635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LINC00665 promotes the viability, migration and invasion of T cell acute lymphoblastic leukemia cells by targeting miR-101 via modulating PI3K/Akt pathway.
    Abuduer M; A EZG
    Tissue Cell; 2021 Aug; 71():101579. PubMed ID: 34171521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defining the molecular basis of oncogenic cooperation between TAL1 expression and Pten deletion in T-ALL using a novel pro-T-cell model system.
    Bornschein S; Demeyer S; Stirparo R; Gielen O; Vicente C; Geerdens E; Ghesquière B; Aerts S; Cools J; de Bock CE
    Leukemia; 2018 Apr; 32(4):941-951. PubMed ID: 29151585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogenic transcriptional program driven by TAL1 in T-cell acute lymphoblastic leukemia.
    Tan TK; Zhang C; Sanda T
    Int J Hematol; 2019 Jan; 109(1):5-17. PubMed ID: 30145780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The subclonal complexity of STIL-TAL1+ T-cell acute lymphoblastic leukaemia.
    Furness CL; Mansur MB; Weston VJ; Ermini L; van Delft FW; Jenkinson S; Gale R; Harrison CJ; Pombo-de-Oliveira MS; Sanchez-Martin M; Ferrando AA; Kearns P; Titley I; Ford AM; Potter NE; Greaves M
    Leukemia; 2018 Sep; 32(9):1984-1993. PubMed ID: 29556024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. S1P-S1PR3-RAS promotes the progression of S1PR3
    Zhu D; Jiang T; Ma D; Zhang H; Zhang J; Lv W; Gong M; Wang H; Liu Z; Su H; Zeng L; Liu S; Tang S; Yang B; Tshavuka FI; Fu G; Liu Z; Peng D; Liu H; Yan Z; Cao Z; Zhao H; He TC; Yu J; Shu Y; Zou L
    Leukemia; 2023 Oct; 37(10):1982-1993. PubMed ID: 37591940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The TAL1 complex targets the FBXW7 tumor suppressor by activating miR-223 in human T cell acute lymphoblastic leukemia.
    Mansour MR; Sanda T; Lawton LN; Li X; Kreslavsky T; Novina CD; Brand M; Gutierrez A; Kelliher MA; Jamieson CH; von Boehmer H; Young RA; Look AT
    J Exp Med; 2013 Jul; 210(8):1545-57. PubMed ID: 23857984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy.
    Ksionda O; Mues M; Wandler AM; Donker L; Tenhagen M; Jun J; Ducker GS; Matlawska-Wasowska K; Shannon K; Shokat KM; Roose JP
    PLoS One; 2018; 13(5):e0193849. PubMed ID: 29799846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NKX3.1 is a direct TAL1 target gene that mediates proliferation of TAL1-expressing human T cell acute lymphoblastic leukemia.
    Kusy S; Gerby B; Goardon N; Gault N; Ferri F; Gérard D; Armstrong F; Ballerini P; Cayuela JM; Baruchel A; Pflumio F; Roméo PH
    J Exp Med; 2010 Sep; 207(10):2141-56. PubMed ID: 20855495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of novel lncRNAs regulated by the TAL1 complex in T-cell acute lymphoblastic leukemia.
    Ngoc PCT; Tan SH; Tan TK; Chan MM; Li Z; Yeoh AEJ; Tenen DG; Sanda T
    Leukemia; 2018 Oct; 32(10):2138-2151. PubMed ID: 29654272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The depletion of Circ-PRKDC enhances autophagy and apoptosis in T-cell acute lymphoblastic leukemia via microRNA-653-5p/Reelin mediation of the PI3K/AKT/mTOR signaling pathway.
    Ling Z; Fang ZG; Wu JY; Liu JJ
    Kaohsiung J Med Sci; 2021 May; 37(5):392-401. PubMed ID: 33615686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of super-enhancer-driven TAL1 expression by KLF4 in T-cell acute lymphoblastic leukemia.
    Noura M; Matsuo H; Yasuda T; Tsuzuki S; Kiyoi H; Hayakawa F
    Oncogene; 2024 Feb; 43(6):447-456. PubMed ID: 38102337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia.
    Canté-Barrett K; Spijkers-Hagelstein JA; Buijs-Gladdines JG; Uitdehaag JC; Smits WK; van der Zwet J; Buijsman RC; Zaman GJ; Pieters R; Meijerink JP
    Leukemia; 2016 Sep; 30(9):1832-43. PubMed ID: 27174491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.